TCL Archive Extent Of Risk Reduction From Ovary Removal Varies According To BRCA Mutation February 29, 2008
TCL Archive Cancer Groups Endorse Richard Pazdur for Head of FDA’s New Office of Oncology Drug Products. Five Candidates Are In the Running for the Job, Sources Said. February 18, 2005
TCL Archive Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival November 29, 2013
TCL Archive Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial July 25, 2014
